Protocol Ledger

NCT05009992 · Phase II · RECRUITING

Combination Therapy for the Treatment of Diffuse Midline Gliomas

Interventional Phase II clinical trial protocol NCT05009992 sponsored by UCSF in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-10-20 Enrollment: 360 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05009992
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)360 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05009992
Protocol FieldVerified Registry Value
NCT IdentifierNCT05009992
Consolidated Lead SponsorUCSF
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment360 participants (ESTIMATED)
Registered Start Date2021-10-20
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for UCSF Health across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI